Is it the reconstruction or the complication? Factors associated with time to adjuvant chemotherapy after breast cancer surgery
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, cilt.53, sa.1, ss.112355, 2027 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 53 Sayı: 1
- Basım Tarihi: 2027
- Doi Numarası: 10.1016/j.ejso.2026.112355
- Dergi Adı: EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
- Derginin Tarandığı İndeksler: Scopus, Science Citation Index Expanded (SCI-EXPANDED), EMBASE, MEDLINE
- Sayfa Sayıları: ss.112355
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
Introduction
Breast reconstruction may delay adjuvant chemotherapy, but whether delays are driven by reconstruction itself or by postoperative complications is unclear.
Materials and methods
This two-centre retrospective cohort study included 187 patients who received adjuvant chemotherapy after breast cancer surgery between January 2019 and June 2024. Delay was defined as initiation more than 42 days after surgery. Multivariable logistic regression evaluated reconstruction status, surgical approach, reconstruction method and Clavien–Dindo complication severity; time to chemotherapy was also analysed as a continuous outcome. Firth regression, bootstrap resampling and sensitivity analyses assessed robustness.
Results
Mean time to chemotherapy was 39.6 ± 12.8 days; 72 patients (38.5%) started after 42 days and none after 90 days. Reconstruction (aOR 4.42, 95% CI 2.10–9.32) and complications (aOR 3.13, 95% CI 1.45–6.75) were independently associated with delay, lengthening the interval by an adjusted 8.8 and 8.2 days, respectively. Risk was highest after autologous or combined reconstruction (aOR 5.92, 95% CI 2.14–16.39) and Clavien–Dindo grade III complications (Firth aOR 7.27, 95% CI 2.26–29.95), whereas grade I–II complications were not associated with delay. Findings were consistent in patients who underwent mastectomy only (reconstruction aOR 3.33, 95% CI 1.32–8.44).
Conclusion
Both reconstruction and, particularly, complications requiring reintervention were associated with a modest delay in adjuvant chemotherapy that remained within the interval regarded as oncologically safe. Preventing severe complications may allow patients to benefit from reconstruction without compromising timely systemic therapy.